Biotron Limited (BITRF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Sydney, NSW, Australia. El CEO actual es Michelle Miller GCertAppFin.
BITRF tiene fecha de IPO 2013-03-22, cotiza en el Other OTC, una capitalización de mercado de $29.15M.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
